TSHA.NASDAQTaysha Gene Therapies, INC
10-K: Taysha Gene Therapies Reports 2024 Results, Highlights Rett Syndrome Program Progress
Sentiment:
Annual Results
Taysha Gene Therapies' 2024 10-K filing details the company's financial performance and clinical advancements, particularly in its TSHA-102 program for Rett syndrome.
Summary
- Taysha Gene Therapies, a clinical-stage biotechnology company, filed its 10-K report for the fiscal year ended December 31, 2024.
- The company is focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system, with its lead program, TSHA-102, targeting Rett syndrome.
- TSHA-102 is currently in Phase 1/2 clinical trials, with data from Part A supporting advancement toward a pivotal Part B trial.
- As of February 17, 2025, TSHA-102 was generally well tolerated in the REVEAL trials, with no treatment-related serious adverse events or dose-limiting toxicities reported in the 10 patients dosed in Part A.
- The company expects to report safety and efficacy data from cohort two of each of the REVEAL trials and an update on safety and efficacy data from cohort one of each of the REVEAL trials, as well as an update on the anticipated pivotal trial design for TSHA-102, in the first half of 2025.
- The FDA has granted orphan drug designation, rare pediatric disease designation, and Fast Track Designation to TSHA-102 for the treatment of Rett syndrome.
- The company has deprioritized the evaluation of clinical product candidates TSHA-105 for SLC13A5, TSHA-118 for CLN1 and TSHA-121 for CLN7.
- Taysha incurred net losses of $89.3 million in 2024 and $111.6 million in 2023, with an accumulated deficit of $602.3 million as of December 31, 2024.
- The company believes its existing cash and cash equivalents of $139.0 million will be sufficient to fund operations into the fourth quarter of 2026.
- Taysha relies on collaborations, particularly with UT Southwestern, for preclinical research and development.
- The company is subject to various healthcare laws and regulations, including the Anti-Kickback Statute and the False Claims Act.
- The company is also subject to data privacy and security obligations, including GDPR and CCPA.
- As of December 31, 2024, Taysha had 73 full-time employees.
Sentiment
Score: 6
Explanation: The document presents a mixed sentiment. While there's progress in clinical trials and regulatory designations, the company faces significant financial challenges and risks.
Positives
- TSHA-102 has shown promising early results in clinical trials and has received key regulatory designations.
- The company has a clear clinical development plan for TSHA-102, with ongoing discussions with the FDA.
- The company has a strong intellectual property portfolio, with in-licensed patents extending to 2043.
- The company has a strong cash position, expected to fund operations into the fourth quarter of 2026.
- The FDA endorsed Taysha's intended GMP commercial manufacturing process for TSHA-102.
Negatives
- The company has a history of significant net losses and an accumulated deficit.
- The company has deprioritized the evaluation of clinical product candidates TSHA-105 for SLC13A5, TSHA-118 for CLN1 and TSHA-121 for CLN7.
- The company is dependent on third parties for manufacturing and clinical trial execution.
- The company is subject to various healthcare laws and regulations, increasing compliance complexity.
Risks
- Clinical trials may not be successful, and regulatory approvals may be delayed or not received.
- The company may face competition from other biotechnology and pharmaceutical companies.
- The company may be subject to legal proceedings and claims.
- The company's term loan agreement contains restrictions that could limit its flexibility.
- The company may be unable to obtain or protect intellectual property rights.
- The company may need to raise additional capital, which may cause dilution to stockholders.
- The company is dependent on third parties for manufacturing and clinical trial execution.
- The company is subject to various healthcare laws and regulations, increasing compliance complexity.
- The company may be subject to data privacy and security breaches.
Future Outlook
The company expects to continue to incur significant expenses and operating losses for the foreseeable future and believes its existing cash and cash equivalents will be sufficient to fund operations into the fourth quarter of 2026.
Industry Context
The company operates in the competitive gene therapy field, facing competition from other biotechnology and pharmaceutical companies, including those with greater resources and experience.
Comparison to Industry Standards
- The document does not contain specific comparisons to industry standards.
- The document does not contain specific comparisons to comparible companies.
- The document does not contain specific comparisons to comparible projects.
- The document does not contain specific comparisons to comparible results.
Legal Proceedings
- The Company was named a nominal defendant in two putative stockholder derivative actions filed by stockholders of the Company in the Court of Chancery of the State of Delaware.
Stakeholder Impact
- Positive impact on patients with Rett syndrome if TSHA-102 is successful.
- Potential risks for shareholders due to financial losses and market volatility.
- Potential impact on employees due to organizational changes and cost reduction plans.
Next Steps
- Report safety and efficacy data from cohort two of each of the REVEAL trials and an update on safety and efficacy data from cohort one of each of the REVEAL trials, as well as an update on the anticipated pivotal trial design for TSHA-102, in the first half of 2025.
Key Dates
| Date | Description |
|---|---|
| 2019-09-01 | Taysha Gene Therapies, Inc. was incorporated under the laws of the State of Texas in September 2019. |
| 2020-02-13 | Taysha converted to a Delaware corporation. |
| 2020-07-01 | The board of directors approved the 2020 Equity Incentive Plan. |
| 2020-08-14 | The Company entered into license and inventory purchase agreements with Abeona Therapeutics Inc. for worldwide exclusive rights to certain intellectual property rights and know-how relating to the research, development and manufacture of ABO-202, an AAV-based gene therapy for CLN1 disease. |
| 2020-09-16 | The Companys stockholders approved the 2020 Stock Incentive Plan and the Employee Stock Purchase Plan. |
| 2020-10-29 | The Company entered into a license agreement with Abeona pursuant to which the Company obtained an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses under certain patents, know-how and materials originally developed by the University of North Carolina at Chapel Hill, the University of Edinburgh and Abeona to research, develop, manufacture, have manufactured, use, and commercialize licensed products for gene therapy and the use of related transgenes for Rett syndrome. |
| 2020-12-17 | The Company entered into a lease agreement with Patriot Park Partners II, LLC, a Delaware limited liability company, pursuant to which the Company agreed to lease approximately 187,500 square feet of a manufacturing facility located at 5 National Way, Durham, North Carolina. |
| 2021-01-11 | The Company entered into a lease agreement with Pegasus Park, LLC, a Delaware limited liability company, pursuant to which the Company leases approximately 15,000 square feet of office space at 3000 Pegasus Park Drive, Dallas, Texas 75247. |
| 2021-07-01 | The Company adopted a 401(k) retirement savings plan that provides retirement benefits to all full-time employees. |
| 2021-08-12 | The Company entered into a Loan and Security Agreement with Silicon Valley Bank. |
| 2021-10-05 | The Company filed a shelf registration statement on Form S-3 with the SEC in relation to the registration of common stock, preferred stock, debt securities, warrants and units or any combination thereof up to a total aggregate offering price of $350.0 million. |
| 2021-12-14 | The Company amended the Dallas Lease with the Dallas Landlord, pursuant to which the Company leases approximately 18,000 square feet of office space adjacent to the Office Space at 3000 Pegasus Park Drive, Dallas, Texas 75247. |
| 2022-03-01 | The Companys CTA filing for TSHA-102 for the treatment of Rett Syndrome was approved by Health Canada. |
| 2022-03-01 | The Company implemented changes to the Companys organizational structure as well as a broader operational cost reduction plan to enable the Company to focus on specific clinical-stage programs for GAN and Rett syndrome. |
| 2022-04-01 | The Company sold 2,000,000 shares of common stock under the Sales Agreement and received net proceeds of $11.6 million. |
| 2022-10-21 | The Company entered into the Option Agreement with Astellas granting Astellas an exclusive option to obtain exclusive, worldwide, royalty and milestone-bearing rights and licenses related to TSHA-120 and TSHA-102. |
| 2022-10-21 | The Company entered into the Securities Purchase Agreement with Astellas, pursuant to which the Company agreed to issue and sell to Astellas an aggregate of 7,266,342 shares of its common stock, for aggregate proceeds of $30.0 million. |
| 2022-10-26 | The Company entered into the Underwriting Agreement, to issue and sell 14,000,000 shares of its common stock, par value $0.00001 per share, in an underwritten public offering pursuant to effective registration statement on Form S-3 and a related prospectus and prospectus supplement. |
| 2023-02-01 | The Company issued options to purchase 70,235 shares of common stock to employees under the New Plan that contain performance-based vesting conditions, subject to continued employment through each anniversary and achievement of the performance conditions. |
| 2023-02-01 | The Company issued options to purchase 70,233 shares of common stock to employees under the New Plan that contain a market-based vesting condition, subject to continued employment through each anniversary and achievement of the market condition. |
| 2023-04-01 | The Company entered into a securities purchase agreement with two affiliates of SSI Strategy Holdings LLC, pursuant to which the Company agreed to issue and sell to the SSI Investors in a private placement, 705,218 shares of its common stock, and warrants to purchase an aggregate of 525,000 shares of its common stock. |
| 2023-05-01 | The Company issued options to purchase 2,166,653 shares of common stock to employees under the New Plan that contain both service and performance-based vesting conditions. |
| 2023-05-01 | The Company dosed the first patient with TSHA-102 in the Phase 1/2 REVEAL trial evaluating the safety and preliminary efficacy of TSHA-102 in adult patients with Rett syndrome. |
| 2023-08-14 | The Company entered into a Securities Purchase Agreement with certain institutional and other accredited investors, pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction, 122,412,376 shares of its common stock and pre-funded warrants to purchase 44,250,978 shares of common stock in lieu of shares of common stock. |
| 2023-09-01 | Astellas provided written notice of its decision not to exercise the GAN Option. |
| 2023-11-13 | The Company entered into a Loan and Security Agreement with Trinity Capital Inc. |
| 2023-12-01 | The Company modified all of the Original Options to amend the clinical and regulatory performance conditions and decreased the number of options granted to 1,516,655. |
| 2023-12-07 | An initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act was announced. |
| 2023-12-08 | The National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. |
| 2023-12-15 | The Companys board of directors adopted the Taysha Gene Therapies, Inc. 2023 Inducement Plan. |
| 2024-01-01 | The Company initiated the return of the FDA Investigational New Drug application and transfer of the investigational clinical trial material for TSHA-120 in GAN to NINDS. |
| 2024-01-01 | The Company gave notice of termination of the GAN License Agreement. |
| 2024-02-01 | The Company received Innovative Licensing and Access Pathway, or ILAP, designation for TSHA-102 from the U.K. MHRA. |
| 2024-04-01 | The FDA granted Regenerative Medicine Advanced Therapy, or RMAT, designation for TSHA-102 in Rett syndrome. |
| 2024-06-26 | The Company entered into an underwriting agreement with Jefferies LLC and Goldman Sachs & Co. LLC to issue and sell 14,361,113 shares of its common stock and pre-funded warrants to purchase 18,972,221 shares of its common stock. |
| 2024-07-09 | The Underwriters exercised their option to purchase an additional 3,235,000 shares of common stock. |
| 2024-07-09 | The GAN License Agreement termination became effective. |
| 2024-08-15 | HHS announced the agreed-upon price of the first ten drugs that were subject to price negotiations. |
| 2024-12-01 | A new European Commission took office. |
| 2024-12-12 | The Companys board of directors reserved an additional 2,000,000 shares of the Companys common stock for issuance under the Inducement Plan. |
| 2024-12-13 | The Company filed a new shelf registration statement on Form S-3 following the expiration of its prior registration statement, in relation to the registration of common stock, preferred stock, debt securities, warrants and units or any combination thereof up to a total aggregate offering price of $300.0 million. |
| 2025-01-17 | HHS selected fifteen additional products covered under Part D for price negotiation in 2025. |
| 2025-02-17 | Data cutoff date for TSHA-102 REVEAL trials. |
| 2025-02-26 | The registrant had 205,001,632 shares of common stock outstanding. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.